following a full submission:
pembrolizumab (Keytruda®) is accepted for use within NHSScotland.
Indication under review: in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.
In a double-blind, phase III study, addition of pembrolizumab to carboplatin plus paclitaxel chemotherapy significantly improved progression-free survival in adults undergoing first-line treatment of primary advanced or recurrent endometrial carcinoma.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2767
- Indication:
In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 July 2025